EP2245155A4 - Verfahren zum sequentiellen austausch eines zielbereichs mittels homologer rekombination - Google Patents

Verfahren zum sequentiellen austausch eines zielbereichs mittels homologer rekombination

Info

Publication number
EP2245155A4
EP2245155A4 EP08860613A EP08860613A EP2245155A4 EP 2245155 A4 EP2245155 A4 EP 2245155A4 EP 08860613 A EP08860613 A EP 08860613A EP 08860613 A EP08860613 A EP 08860613A EP 2245155 A4 EP2245155 A4 EP 2245155A4
Authority
EP
European Patent Office
Prior art keywords
methods
homologous recombination
targeted region
sequential replacement
sequential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08860613A
Other languages
English (en)
French (fr)
Other versions
EP2245155A2 (de
Inventor
Hiroaki Shizuya
Manish Singh
Cecilia Roh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablexis LLC
Original Assignee
Aliva Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliva Biopharmaceuticals Inc filed Critical Aliva Biopharmaceuticals Inc
Publication of EP2245155A2 publication Critical patent/EP2245155A2/de
Publication of EP2245155A4 publication Critical patent/EP2245155A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP08860613A 2007-12-10 2008-12-10 Verfahren zum sequentiellen austausch eines zielbereichs mittels homologer rekombination Withdrawn EP2245155A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1270107P 2007-12-10 2007-12-10
PCT/US2008/086275 WO2009076464A2 (en) 2007-12-10 2008-12-10 Methods for sequential replacement of targeted region by homologous recombination

Publications (2)

Publication Number Publication Date
EP2245155A2 EP2245155A2 (de) 2010-11-03
EP2245155A4 true EP2245155A4 (de) 2011-05-25

Family

ID=40756107

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08860613A Withdrawn EP2245155A4 (de) 2007-12-10 2008-12-10 Verfahren zum sequentiellen austausch eines zielbereichs mittels homologer rekombination

Country Status (7)

Country Link
US (1) US20110119779A1 (de)
EP (1) EP2245155A4 (de)
KR (1) KR20100103810A (de)
AU (1) AU2008335178A1 (de)
CA (1) CA2708776A1 (de)
NZ (1) NZ586149A (de)
WO (1) WO2009076464A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
NO2516457T3 (de) * 2009-12-21 2018-08-11
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3741862A1 (de) 2011-09-19 2020-11-25 Kymab Limited Tiere, repertoires und verfahren dafür
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2831245A1 (de) 2012-03-28 2015-02-04 Kymab Limited Transgene nichtmenschliche wirbeltiere für die expression von vollständig humanen antikörpern mit geänderter klasse
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP3912464A1 (de) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanisierte nichtmenschliche tiere mit eingeschränkten schwerkettigen immunglobulin-loci
MY185881A (en) 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6689610B1 (en) * 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
DE69133557D1 (de) * 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
GB9119338D0 (en) * 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
BR9808584A (pt) * 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6090554A (en) * 1997-10-31 2000-07-18 Amgen, Inc. Efficient construction of gene targeting vectors
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
JP3967866B2 (ja) * 2000-04-28 2007-08-29 パイオニア株式会社 ナビゲーション装置及びナビゲーションプログラムがコンピュータで読取可能に記録された情報記録媒体
US7105348B2 (en) * 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2463233A1 (en) * 2001-06-26 2003-01-09 Genome Biosciences, Llc Gene targeting methods and vectors
US20050118648A1 (en) * 2001-09-27 2005-06-02 Limin Li Methods and combinations for gene targeting by homologous recombination
AU2002351233A1 (en) * 2001-12-04 2003-06-17 Genome Biosciences, Llc Gene targeting methods and vectors
JP3743394B2 (ja) * 2002-05-31 2006-02-08 株式会社村田製作所 赤外線センサおよびそれを用いた電子装置
TW588243B (en) * 2002-07-31 2004-05-21 Trek 2000 Int Ltd System and method for authentication
AU2003278790A1 (en) * 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
US7205148B2 (en) * 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
JP2005189662A (ja) * 2003-12-26 2005-07-14 Fujitsu Display Technologies Corp 液晶表示装置及びその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAMSAI D ET AL: "A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia", GENOMICS, vol. 88, no. 3, 1 September 2006 (2006-09-01), ACADEMIC PRESS, SAN DIEGO, US, pages 309 - 315, XP024929433, ISSN: 0888-7543, [retrieved on 20060901], DOI: 10.1016/J.YGENO.2006.03.009 *
SOSIO M ET AL: "Assembly of large genomic segments in artificial chromosomes by homologous recombination in Escherichia coli.", NUCLEIC ACIDS RESEARCH, vol. 29, no. 7, E37, 1 April 2001 (2001-04-01), pages 1 - 8, XP002630416, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
AU2008335178A1 (en) 2009-06-18
EP2245155A2 (de) 2010-11-03
WO2009076464A3 (en) 2009-09-24
WO2009076464A2 (en) 2009-06-18
US20110119779A1 (en) 2011-05-19
KR20100103810A (ko) 2010-09-28
NZ586149A (en) 2012-05-25
CA2708776A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
IL254498A0 (en) Methods for preparing purified polypeptide preparations
IL220616A0 (en) Novel 3 - hydroxy - 5 - arylisothiazole derivative
IL214729A0 (en) Oxyntomodulin analogs
EP2412708A4 (de) Substituiertes 3-hydroxy-4-pyridonderivat
EP2514747A4 (de) Substituiertes aminothiazinderivat
EP2495238A4 (de) Neues 3-hydroxy-5-arylisoxazolderivat
IL212412A0 (en) Femto-cell location by direct methods
ZA201006736B (en) Expression of heterologous sequences
IL220472A0 (en) Improved techniques for transfecting protoplasts
PT2343292E (pt) Novo derivado de prostaglandina i2
EP2573047A4 (de) Verfahren zur herstellung von zwiebelähnlichem kohlenstoff
GB0900404D0 (en) New compounds 4
HRP20190160T8 (hr) Mutant gdf-5 za indukciju formiranja hrskavice
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
GB0912946D0 (en) New compounds 5
EP2509715A4 (de) Werkzeuglos und schnell auswechselbare ventilstange
IL214319A0 (en) Cholestanol derivative for combined use
GB0805281D0 (en) Homologous recombination
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
TWI347168B (en) Plant senescence-inducible promoter
GB0904444D0 (en) Chamber 4
GB0902077D0 (en) Chamber 3
GB0922346D0 (en) Improved chamber
GB0900392D0 (en) New compounds 2
GB0900400D0 (en) New compounds 3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100709

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110421

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABLEXIS, LLC

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17Q First examination report despatched

Effective date: 20140626

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141107